Know Cancer

or
forgot password

Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy


Inclusion Criteria:



- Women aged more than 18 years

- Histologically proven breast carcinoma

- Neo-adjuvant chemotherapy with anthracyclines and/or taxanes

- No prior chemotherapy

- Written informed consent

Exclusion Criteria:

- Metastatic disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Proteomic analysis by SELDI-TOF on the tumor biopsy and blood samples Histological response according To Chevallier and Sataloff

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

BONNETERRE Jacques, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Oscar Lambret

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

SPAM 2006-10

NCT ID:

NCT00911911

Start Date:

January 2007

Completion Date:

July 2009

Related Keywords:

  • Breast Cancer
  • Breast cancer
  • Neo-adjuvant chemotherapy
  • Proteomic
  • Histological response
  • Breast Neoplasms

Name

Location